In particular, Q48 and Q54 were able to inhibit ERK1/2 activation in GBM 3 and 19, and metformin only in GBM 3; conversely GBM 23 was not responsive to all the tested compounds. The gene discussed is MAPK3; the disease is glioblastoma.